SEC Form 4 · accession 0001600132-19-000015
Bellerophon Therapeutics, Inc. · BLPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Fabian Tenenbaum
Officer — Chief Executive Officer
Period of report
Jan 2, 2019
Accepted (ET)
Jan 4, 2019 · 4:29 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001600132
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $0.88 | Jan 2, 2019 | A | 12,500 | A | — | Jan 2, 2029 | Common Stock | 12,500 | 3,688,697 | D |
Explanation of responses
- F11. This option was granted on January 2, 2019. This option vests in quarterly installments over a four-years period from the date of grant.